All the Drug Class Drugs
Somatostatin Analog. Octreotide 0.1 mg/ml, 0.5 mg/ml. AMP.Sol. for inj/inf. 10X 1 ml for SC/IV
Acromegaly Initially 0.05 to 0.1 mg by s.c.inject. every 8 or 12 hours. Dosage adjustm. should be based on monthly assessment of GH and IGF-1 levels (target: GH<2.5 ng/mL; IGF-1 within normal range) and clin. sympt., and on tolerability. In most pts, the optimal dly dose will be 0.3 mg. A max. dose of 1.5 mg /d should not be exceeded. For pts on a stable dose, assessment of GH should be made every 6 months. If no relevant reduct. in GH levels and no improvement in clin. sympt. have been achieved within 3 months of tmt. with this drug, ther. should be discontinued.
Gastro-entero-pancreatic endocrine tumours Initially 0.05 mg once or twice/d by s.c. inject. Depending on clin. respon., effect on levels of tumour-produced hnes. (in cases of carcinoid tumours, on the urinary excretion of 5-hydroxyindole acetic acid), and on tolerability, dosage can be gradually incr. to 0.1 to 0.2 mg 3 times/d. Under exceptional circumstances, higher doses may be req. Maint. doses have to be adjusted individually. In carcinoid tumours, if there is no beneficial respon. within 1 week of tmt. with this drug at the max toler. dose, ther. should not be continued.
Complications following pancreatic surgery 0.1 mg 3 times/d by s.c. inj. for 7 consecutive days, starting on the day of operation at least 1 hour before laparotomy.
Bleeding gastro-oesophageal varices 25 micrograms/h for 5 d by continuous i.v. infusion. This drug can be used in dilution with physiological saline. In cirrhotic pts with bleeding gastro-oesophageal varices, this drug has been well tolerat. at continuous i.v. doses of up to 50 micrograms/h for 5 days.
Prevention of complicat. following pancreatic surgery. Symptomatic control and reduction of GH and IGF-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. This treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. Relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - Carcinoid tumours with features of the carcinoid syndrome - VIPomas - Glucagonomas - Gastrinomas / zollinger-Ellison syndrome usually in conjunction with proton pump inhibitors or H2- antagonist therapy - Insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - GRFomas. This drug is not an antitumour therapy and is not curative in these patients. Emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.
C/I: Hypersens.
Somatostatin Analog. Octreotide 10, 20, 30 mg. VIALS: 1. (2 vehicle amp + 1 inject set).
By deep intraglut. inject. See lit.
Acromeg. in pts. adequat. controlled on
standard dose Sandostatin S.C. in whom
surg. radiother., or dopamine-agonist tmt.
inapprop. or ineffect., in latency period bef.
radiother. becomes fully effect. Endocrine
gastro-entro-pancreat. (GEP) tumors,
carcinoid tumors.
VIALS: 1. (1 prefilled syringe + 2 needles)
x 20 mg, 30 mg. By deep intraglut.
inject. See lit.
Acromeg. in pts. adequat. controlled on
standard dose Sandostatin S.C. in whom
surg. radiother. inapprop. or ineffect., in
latency period bef. radiother. becomes
fully effect. Endocrine gastro-entropancreat.
(GEP) tumors, carcinoid
tumors.
Somatostatin Analog. Lanreotide (as acetate) 60, 90, 120 mg. PRE-FILLED SYRINGE: 1. Deep S.C. into
ior ext. quad. of buttock. See Lit.
Acromeg. (when tmt. growth hormone not
normaliz. aft. surg. and/or radiother.),
clinical sympts. carcinoid tumors (aft. test
inject.).
C/I: Hypersens., pregn., lact.
